CEO Joseph Burnett stated that ClearPoint Neuro ended 2025 on its strongest financial quarter of the year, highlighting "a newly acquired and commercialized neurocritical care product line and genuine ...
ClearPoint Neuro reported Q3 2025 revenue of $8.9M, up 9% YoY, with gross margin improving to 63%. Management reaffirmed 2025 revenue guidance of $36–38M and introduced 2026 pro forma guidance of ...
ClearPoint Neuro delivered Q2 2026 revenue of $10.9M, up 18% YoY, with notable segment variability: strong neurosurgery navigation and capital equipment growth offset a 15% decline in biologics and ...
[Audio Gap] comments made on this call may include statements that are forward-looking within the meaning of securities laws. These forward-looking statements may include, without limitation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results